A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine-Reference-Cited by-同舟云学术

A drug interaction study evaluating the pharmacokinetics and toxicity of sorafenib in combination with capecitabine

Published:2011-05-28 Issue:1 Volume:69 Page:137-144
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Infante Jeffrey R.,Jones Suzanne F.,Bendell Johanna C.,Greco F. Anthony,Yardley Denise A.,Lane Cassie M.,Spigel David R.,Hainsworth John D.,Burris III Howard A.

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00280-011-1674-0.pdf

Reference21 articles.

1. Escudier B, Eisen T, Stadler WM et al (2007) Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 356:125–134

2. Llovet JM, Ricci S, Mazzaferro V et al (2008) Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359:378–390

3. Jemal A, Murray T, Ward E et al (2005) Cancer statistics, 2005. CA Cancer J Clin 55:10–30

4. Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64:7099–7109

5. Xeloda® Tablets package insert. New Jersey Roche Laboratories, Inc.:April 2006

Cited by 9 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pharmacokinetics and Comparative Bioavailability of Test or Reference Capecitabine and Discrepant Pharmacokinetics Among Various Tumors in Chinese Solid Cancer Patients;Clinical Pharmacology in Drug Development;2023-01-15

2. Population pharmacokinetic analyses of regorafenib and capecitabine in patients with locally advanced rectal cancer (SAKK 41/16 RECAP);British Journal of Clinical Pharmacology;2022-07-23

3. In vivo assessment of potential for UGT-inhibition-based drug-drug interaction between sorafenib and tapentadol;Biomedicine & Pharmacotherapy;2020-10

4. Clinical Pharmacokinetics and Pharmacodynamics of Transarterial Chemoembolization and Targeted Therapies in Hepatocellular Carcinoma;Clinical Pharmacokinetics;2019-05-15

5. Inefficiencies and Patient Burdens in the Development of the Targeted Cancer Drug Sorafenib: A Systematic Review;PLOS Biology;2017-02-03